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Arenavirus hemorrhagic fevers are 
devastating emerging human diseases
Viral hemorrhagic fevers (VHFs) are severe 
human diseases that show different clinical 
courses and are associated with the cardinal 
symptoms of fever, hemorrhages and shock. A 
wide variety of viruses that belong to different 
virus families can cause VHFs, including the 
filoviruses (Ebola and Marburg hemorrhagic 
fever [HF]), the arenaviruses (Lassa fever, 
Argentine HF [AHF], Bolivian HF, Venezuelan 
HF and Brazilian HF), bunyaviruses (Crimean 
Congo HF and Rift Valley fever) and flavi-
viruses (Yellow fever and Dengue HF) [1]. The 
arenaviruses are a large and diverse family of 
enveloped RNA viruses that include several 
causative agents of severe VHFs, which belong 
to the most devastating emerging human dis-
eases and serious public health problems [1,2]. 
Arenavirus VHFs in humans are acute diseases 
characterized by fever and, in severe cases, dif-
ferent degrees of hemorrhages associated with 
a shock syndrome in the terminal stage. The 
most prevalent pathogen among the arenavi-
ruses is Lassa virus (LASV), the causative agent 
of Lassa fever that is endemic to West Africa 
from Senegal to Cameroon and causes several 
hundred thousand infections per year with thou-
sands of deaths [3]. The mortality of hospitalized 
Lassa fever patients is 15–30% and can reach 
more than 50% in some outbreaks. There is 
currently no vaccine available and therapeutic 
intervention is limited to intensive care and the 
use of ribavirin, which shows some efficacy when 
given early in disease. On the South American 
continent, the arenaviruses Junin virus (JUNV), 
Machupo virus (MACV), Guanarito virus 
(GTOV) and Sabia virus (SABV) have emerged 
as etiological agents of severe VHF in Argentina, 
Venezuela, Bolivia and Brazil, respectively [2]. 
The prototypic arenavirus lymphocytic chorio-
meningitis virus (LCMV), which is distributed 
worldwide, is also a neglected human pathogen 
of clinical significance, especially in pediatric 
medicine [4,5] and represents a threat to immu-
nocompromised individuals [6,7]. Considering 
the number of people affected and the unad-
dressed need for better therapeutics, arenaviruses 
arguably belong to the most neglected tropical 
pathogens. Apart from the severe humanitarian 
burden in endemic regions, arenavirus HF cases 
are regularly imported into metropolitan areas 
around the globe, placing local populations at 
risk [8]. This article will briefly cover some gen-
eral aspects of the classification, epidemiology 
and basic virology of arenaviruses, and will then 
provide a more detailed overview of the clini-
cal disease, and in particular the pathogenesis 
of arenavirus VHFs with an emphasis on recent 
developments in the field. 
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Viral hemorrhagic fevers (VHFs) caused by arenaviruses belong to the most devastating emerging 
human diseases and represent serious public health problems. Arenavirus VHFs in humans are 
acute diseases characterized by fever and, in severe cases, different degrees of hemorrhages 
associated with a shock syndrome in the terminal stage. Over the past years, much has been 
learned about the pathogenesis of arenaviruses at the cellular level, in particular their ability to 
subvert the host cell’s innate antiviral defenses. Clinical studies and novel animal models have 
provided important new information about the interaction of hemorrhagic arenaviruses with 
the host’s adaptive immune system, in particular virus-induced immunosuppression, and have 
provided the first hints towards an understanding of the terminal hemorrhagic shock syndrome. 
The scope of this article is to review our current knowledge on arenavirus VHF pathogenesis 
with an emphasis on recent developments.
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Classification & epidemiology of arenaviruses
The Arenaviridae are currently subdivided into two major sub-
groups, the Old World arenaviruses and the New World arena-
viruses [9,10]. The Old World lineage contains the prototypic 
LCMV, the related Dandenong virus and the African viruses 
LASV, Mopeia, Mobala, Ippy and Morogoro virus. The New 
World arenaviruses are divided into three Clades, A, B and C. 
Clade A includes the South American viruses Pichinde virus, 
Parana virus, Pirital virus, Flexal virus and Allpahuayo virus. A 
North American Clade A/Rec comprises Whitewater Arroyo, 
Bear Canyon, and Tamiami, Catarina and Skinner Tank virus. 
The phylogenetic relationship of these viruses is poorly resolved, 
but there is evidence that a recombination event between Clade 
A and B viruses may be at the origin of this Clade as reviewed by 
Emonet et al. [9]. Whitewater Arroyo virus has been associated 
with three cases of fatal human disease [11,12]. However, a defini-
tive causal relationship has not yet been established. Clade B con-
tains the hemorrhagic viruses JUNV, MACV, GTOV, SABV and 
the recently emerged Chapare virus, as well as the nonpathogenic 
viruses Tacaribe (TACV), Amapari and Cupixi. Clade C contains 
the viruses Oliveros, Latino and Pampa. 
In nature, each arenavirus species is carried by one or a limited 
number of related rodent species, which serve as their natural 
reservoirs. A possible exception is TACV, which has only been 
isolated from the fruit-eating bat species Artibeus. The present 
phylogenetic diversity of arenaviruses is the result of long-term 
co-evolution between viruses and their corresponding host spe-
cies, involving vertical and horizontal transfer of viruses within 
and between populations, respectively, and probably occasional 
genetic recombination events [9,10,13]. 
A particular concern is the continued emergence of novel 
arenaviruses that are associated with fatal human disease. New 
arenaviruses emerge on average every 3 years [9]. In December 
2003, a small cluster of fatal VHF cases was reported in a rural 
area near the Chapare River in Bolivia, Southern America. 
Examination of patient samples allowed the isolation and identi-
fication of Chapare virus, a novel species of arenavirus phyloge-
netically closely related to SABV [14]. More recently, in September 
2008, a nosocomial outbreak of unexplained VHF occurred in 
Zambia, Southern Africa. Five patients were involved and four 
of them died with suspected human-to-human transmission. A 
high-throughput sequencing approach based on unbiased pyro-
sequencing revealed the presence of an arenavirus-like genome 
identified as a new member of the Arenaviridae family called LuJo 
virus according to its geographic distribution: Lusaka, Zambia 
and Johannesburg, South Africa [15]. The high mortality of four 
out of five hospitalized individuals and the strong evidence for 
human-to-human transmission are of particular concern regard-
ing the epidemiological and disease potential of this new member 
of the arenavirus family. 
Human arenavirus infections occur principally by aerosol or close 
contact with rodent excreta, contamination of food and drink or via 
skin abrasions. AHF caused by JUNV has a marked seasonal inci-
dence, coinciding with the maize harvest between April and June 
when feral rodent populations reach their peak [16]. Agricultural 
workers and those in rural communities are thus at greatest 
risk. It is thought that transmission to humans results from the 
virus being carried on dust particles or by direct  ingestion of 
 contaminated foodstuffs. 
Molecular & cell biology of arenaviruses
The basic virology of arenaviruses has been covered by excellent 
recent reviews [2,17] and only a short summary will be given here. 
Arenaviruses are enveloped viruses with a bisegmented negative 
strand RNA genome and a nonlytic life cycle restricted to the cyto-
plasm (Figure 1A). Each genomic RNA segment, L (circa 7.3 kb) and 
S (circa 3.5 kb), uses an ambisense coding strategy to direct the 
synthesis of two polypeptides in opposite orientation, separated by 
a noncoding intergenic region with a predicted hairpin structure 
(Figure 1B). The S RNA encodes the viral glycoprotein (GP) pre-
cursor, which is synthesized as a single polypeptide chain (circa 
75 kDa) and post-translationally cleaved by the cellular proprotein 
convertase subtilisin kexin isozyme-1/site-1 protease to yield the 
mature virion GPs GP1 (40–46 kDa) and GP2 (35 kDa) [18–20], 
and the nucleoprotein (NP; circa 63 kDa). The L RNA encodes the 
viral RNA dependent RNA polymerase (RdRp or L polymerase; 
circa 200 kDa) and a small RING finger protein Z (circa 11 kDa). 
Attachment to the host cell is mediated by the arenavirus GP1, 
which is located at the top of the mature GP spike present in the 
viral envelope. The transmembrane GP2 resembles the fusion-
active membrane-proximal parts of other enveloped viruses. The 
cellular receptor for LASV, most other Old World arenaviruses 
and Clade C New World arenaviruses is a-dystroglycan (a-DG), 
a cell surface receptor for proteins of the extracellular matrix 
[21,22]. The hemorrhagic New World arenaviruses JUNV, MACV, 
GTOV and SABV can use human transferrin receptor 1 (TfR1) 
[23]. Upon attachment to the target cell, arenavirus particles are 
taken up by endocytosis and delivered to acidified endosomes 
where low pH induces membrane fusion [24]. New World are-
naviruses like JUNV that use human TfR1 enter the cell via 
clathrin-mediated endocytosis [25]. In contrast, the Old World 
arenaviruses LASV and LCMV, which depend on a-DG, use a 
distinct and unusual pathway for cell entry that is independent of 
clathrin, caveolin, dynamin and actin [26–28]. Upon penetration 
into the cytoplasm, the viral ribonucleoparticles serves as a tem-
plate for both transcription and replication that is mediated by the 
arenavirus RdRp L. The L and NP proteins are necessary and suf-
ficient for these initial steps of viral transcription and replication 
[17]. Formation and release of arenavirus infectious progeny from 
infected cells occurs by budding during which ribonucleoparticles 
associate at the cell surface with membranes that are enriched in 
viral GPs. In arenaviruses, the Z protein functions as the main 
driving force for viral budding and resembles the matrix proteins 
of other enveloped RNA viruses [29,30]. 
Clinical disease & pathogenesis of Lassa fever
LASV was isolated in 1969 after a hospital outbreak in north-
ern Nigeria [31,32], with additional outbreaks in Nigeria, Liberia 
and Sierra Leone. In 1972, the reservoir of LASV was identi-
fied as the rodent Mastomys natalensis [33]. Currently, LASV is 
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endemic from Senegal to Cameroon [3] with recent emergence in 
Mali [34]. Reliable epidemiological data are missing from most 
affected regions, however, available information on seroprevalence 
for Nigeria, Sierra Leone and Guinea reveal that in some areas, 
20–50% of the adult population have been infected with LASV 
[35], making LASV a major public health problem. Contact with 
urine or feces of persistently infected rodents invading human 
dwellings are the main routes of human transmission, and human-
to-human spread can occur by contact with contaminated blood 
or body fluids [36,37]. The fatality rate of Lassa fever in hospitalized 
patients is between 15 and 20% [38], rising to more than 30% in 
pregnant women in the third trimester with fetal or neonatal loss 
of 88% [39]. The fatality ratio can be as high as 50% or greater in 
nosocomial outbreaks [37].
Acute Lassa fever presents with a wide spectrum of clinical 
manifestations from asymptomatic infection to fatal HF, and 
diagnosis based on early clinical symptoms is often difficult [38]. 
After an incubation period of 7–18 days, patients develop fever, 
weakness and general malaise. A majority 
of patients develop cough, severe headache 
and sore throat. Gastrointestinal manifes-
tations such as nausea, diarrhea and vomit-
ing are frequent. Signs of increased vascular 
permeability such as facial edema and pleu-
ral effusions occur in a minority of patients 
and indicate a poor prognosis. With severe 
cases leading to death, deterioration is 
rapid, occurring between the sixth and 
tenth day of illness with progressive signs 
and symptoms of pulmonary edema, respi-
ratory distress, shock, signs of encephalopa-
thy accompanied with seizures and coma, 
and bleeding from mucosal surfaces. Those 
recovering, generally 2–3 weeks after dis-
ease onset, clear the virus from the blood. 
A complication late in the course of disease 
or in early convalescence is sensorineural 
deafness [40]. 
A highly predictive factor for the out-
come of LASV infection is the extent of 
viremia. Patients with fatal Lassa fever 
have higher viral loads at time of hospi-
talization and are unable to limit viral 
replication, whereas survivors have lower 
initial viral load and control the infection 
[41]. Despite the widespread infection and 
development of shock in terminal stages 
of the disease, histological examination of 
fatal Lassa fever cases showed surprisingly 
little cellular damage and only a mod-
est infiltration of inflammatory cells [42]. 
Hepatic lesions in the form of multifocal 
hepatocellular necrosis were a consistent 
pathological change [42,43]; however, the 
degree of hepatic tissue damage was insuf-
ficient to cause hepatic failure and only minimal recruitment of 
inflammatory cells was observed. High viral titers were detected 
in the lung, spleen, kidney, heart and the adrenal gland [42]. Other 
histological alterations included interstitial pneumonia and acute 
myocarditis. In the spleen, necrosis occurred predominantly in the 
marginal zone of the splenic periarteriolar lymphocytic sheath.
A hallmark of fatal LASV infection in humans is the inability 
of the patient’s innate and adaptive immune system to contain 
the virus, resulting in uncontrolled fatal infection. Instead of 
being recognized and contained by the host cell’s innate defense 
system, pathogenic arenaviruses are able to subvert the normal 
mechanisms of innate pathogen recognition. The elucidation of 
the innate immune defense against arenaviruses and the mecha-
nisms of viral countermeasures have been a particularly active 
area of arenavirus research in the past 5 years. As is the case 
for other RNA viruses, the genomic RNA of arenaviruses can 
be recognized by the cytoplasmic RNA helicases of the reti-
noic acid-inducible gene I (RIG-I) family, which represent the 
Figure 1. Arenavirus particle and genome organization. (A) Schematic 
representation of an arenavirus particle. The viral RNA is packaged into 
ribonucleoparticles (RNPs) containing the viral NP. The RNA-dependent RNA polymerase 
(L) is associated with RNP and is required for the initial steps of viral transcription. The 
matrix protein, Z, associates with the inner leaflet of the viral membrane envelope and 
interacts with the C-terminal part of the transmembrane GP2 moiety of the mature  
GP1/GP2 complex decorating the virion surface. The receptor-binding GP1 forms the top 
part of the GP virion spikes, whereas the transmembrane GP2 part contains the fusion 
machinery. In their mature form, arenavirus GPs are fully processed and presumably form 
trimers, similar to other fusion-active viral membrane proteins. (B) The ambisense coding 
strategy of arenaviruses. Each of the two ssRNA segments, L (circa 7.2 kb) and S (3.5 kb), 
uses an ambisense coding strategy to direct the synthesis of two polypeptides in 
opposite orientations and is separated by an IGR predicted to have a stable hairpin 
structure. The 5’ ends of the genomic arenavirus RNA cannot serve as a template for 
translation and viral protein expression requires prior transcription, as in true  
negative-strand viruses.  
GP: Glycoprotein; GPC: Glycoprotein precursor; IGR: Intergenic region;  
L: RNA-dependent RNA polymerase; NP: Nucleoprotein.
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major innate sensors for viral RNA and induce the production 
of type I interferons (IFNs) [44,45]. However, cells infected with 
arenaviruses are unable to induce a type I IFN response owing 
to the ability of the viral NP to act as an IFN antagonist [46,47]. 
Mechanistically, the NPs of arenaviruses block the activation 
of the transcription factor IFN regulatory factor 3 (IRF3), a 
major downstream regulator of type I IFN induction via RIG-I 
helicases [46]. The ability of arenavirus NP to block type I IFN 
induction is conserved among arenaviruses, with the exception 
of TACV, whose NP is much less efficient [48]. In contrast to Old 
World arenaviruses, where the NP appears to be the only IFN 
antagonist, the matrix protein Z derived from the New World 
HF viruses JUNV, MACV, GTOV and SABV is also able to 
perturb the activation of RIG-I [49]. The Z protein of New World 
HF viruses directly interacts with RIG-I and blocks the activa-
tion of downstream signaling involving IRF3 and NF-kB via the 
adaptor mitochondrial antiviral signaling protein. Interestingly, 
arenaviruses selectively prevent the induction of type I IFNs, but 
do not perturb signaling induced by the addition of exogenous 
type I IFNs [46]. The role of the type I IFN response in survivors 
of LASV infection is not clear. Recent studies in nonhuman 
primates revealed production of type I IFNs early in LASV infec-
tion of animals that survived [50], however, the source of IFN 
has not been clearly identified and it is at present not clear what 
role this IFN response plays in protection. 
Fatal Lassa fever is characterized by a marked suppression of 
both branches of the adaptive immune response, cellular and 
humoral immunity. Surviving Lassa fever patients control the 
infection primarily by cellular immunity, in particular the anti-
viral T-cell response [51,52]. By contrast, antibodies play a modest 
role in acute LASV infection as patients can recover in the absence 
of a neutralizing antibody response [41]. The marked virus-induced 
immunosuppression in fatal Lassa fever likely involves infection 
of antigen-presenting cells (APCs), in particular macrophages 
and dendritic cells (DCs), crucial populations of professional 
APCs required to induce the adaptive antiviral immune response 
(Figure 2) [3]. Infection of human monocyte-derived macrophages 
and DC with LASV in vitro fails to activate the cells and results 
in an impairment of their ability to present antigens to T cells 
[53,54]. LASV infection of macrophages and DCs is not associ-
ated with the release of proinflammatory cytokines [53,54] and 
fatal Lassa fever in humans and nonhuman primates seems not 
to be associated with massive inflammatory and T-cell-derived 
cytokine release [50,55]. 
Another hallmark of LASV infection in humans and non-
human primates is lymphopenia, which is most pronounced in 
fatal cases and associated with tissue damage in lymphoid organs 
[3]. Recent studies in nonhuman primates revealed that both CD4 
and CD8 cells, as well as B cells and NK cells, were affected 
[50]. Since human T and B cells lack a functional LASV receptor 
[56,57], they are not infected, suggesting an indirect effect that 
may involve virus-induced immunoregulatory factors. Possible 
candidates are type I IFNs implicated in lymphopenia observed 
in experimental infection of the mouse with the related arenavirus 
LCMV [58]. 
Although hemorrhages represent a cardinal symptom of arena-
virus VHFs, blood loss does normally not account for the fatal 
outcome of the disease. This is particularly true for Lassa fever, 
where bleeding is not a salient feature and does not significantly 
contribute to the shock syndrome [3]. LASV infection in humans 
is normally associated with only weak thrombocytopenia and 
mild perturbation of platelet function [59,60]. The platelet function 
defect appears to be mediated by a plasma inhibitor that has not yet 
been characterized [60]. Only mild vascular lesions were observed 
in postmortem examination of fatal human Lassa fever cases [42]. 
In contrast to other VHFs, disseminated intravascular coagula-
tion involving activation of fibrin deposition is virtually absent in 
arenavirus VHFs (TABle 1). Virus-induced impairment of vascular 
function is likely central to fatal Lassa fever (Figure 2) and perturba-
tion of the function of endothelial cells precedes the onset of shock 
and death [59,61]. The mechanisms by which LASV infection affects 
endothelial cells are largely unknown and may include direct effects 
of the virus infection and indirect mechanisms, for example. virus-
induced release of soluble factors that impact on endothelial cell 
function. In other VHFs, in particular Ebola and Marburg HF, 
alterations of vascular function have been attributed mainly to the 
virus-induced host responses, in particular excessive production of 
TNF-a, IFN-g and nitric oxide, resembling some aspects of septic 
shock syndrome [62,63]. Initial in vitro studies infecting human 
monocytes/macrophages and human endothelial cells with LASV 
provided the first evidence for important differences between the 
pathogenesis of LASV and filoviruses. LASV infection was highly 
productive in these cell types without causing an overt cytopathic 
effect. In the absence of cell damage, LASV infection resulted in 
reduced levels of proinflammatory cytokines, including TNF-a 
and IL-8 [64]. Detection of proinflammatory cytokines in the sera 
of patients with fatal Lassa fever and experimental infection in non-
human primates have so far revealed little evidence for a ‘cytokine 
storm’ as observed in filovirus VHF [50,55]. Although a possible 
role of host-derived soluble factors in LASV-induced perturbation 
of endothelial cell function in vivo can at present not be ruled out, 
it is conceivable that more direct effects of the virus on vascular 
endothelial cells as a consequence of viral gene expression may 
underlie at least some of the vascular dysfunction observed in fatal 
Lassa fever. In summary, the mechanisms underlying the profound 
shock associated with the terminal stage of fatal Lassa fever in 
humans are still largely unknown. According to a working model 
presented in Figure 2, infection of several cell types in different tis-
sues, including the vascular endothelium, the liver and the adrenal 
cortex, may result in an overall impairment of the regulation of vas-
cular permeability in a direct or indirect way. The terminal shock 
syndrome may involve an imbalance of fluid distribution between 
intravascular and interstitial spaces combined with coagulation 
abnormalities and perhaps dysregulation of blood pressure. 
Clinical disease & pathogenesis of South American 
hemorrhagic fevers
Among the South American HF viruses, JUNV, the causative 
agent of AHF, represents the most important public health prob-
lem, whereas MACV, GTOV and SABV cause only sporadic 
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outbreaks. JUNV was isolated from fatal VHF cases in the humid 
Pampas, the major agricultural area of Argentina, in the 1950s 
[65,66]. The rodent Calomys musculinus serves as the main natu-
ral reservoir of the virus. The virus is occasionally isolated from 
other rodents, possibly because of transmission from the natural 
host population. Former endemic hot spots are currently cool-
ing off, whereas the overall geographic regions affected by the 
disease increases progressively [67]. AHF is a severe illness with 
hemorrhagic and/or neurological manifestations and a fatality 
rate of 15–30% in untreated cases [16,67,68]. JUNV appears to 
be infectious as aerosols and deposits in the terminal respiratory 
bronchioles [69]. Upon early replication in the lung, the virus 
enters into the lymphoid system and spreads systemically. After an 
incubation period of 1–2 weeks, AHF starts with rather unspecific 
symptoms: fever, asthenia, muscular pain, dizziness, skin and 
mucosal rashes, and lymph node swelling. A total of 6–10 days 
after disease onset, symptoms worsen with cardiovascular, gastro-
intestinal, renal and neurological involvement, associated with 
hematologic and hemostatic alterations. Disease manifestations 
are mainly neurological and/or hemorrhagic. Those who recover 
from AHF develop an antiviral immune response including anti-
bodies in the second week of disease and clear the virus [70]. In 
convalescent plasma from AHF survivors, robust titers of neutral-
izing antiviral antibodies, mainly IgG, can be detected. In fatal 
cases, viremia is unchecked and patients succumb to a terminal 
hemorrhagic shock syndrome with a mortality of 15–30% in the 
absence of immune plasma therapy [16,68]. 
Pathological lesions in fatal AHF include generalized vaso-
congestion with multiple hemorrhages in the gastrointestinal 
mucosa, different organs, such as the liver, kidney and lungs, as 
well as subcutaneous tissue. In the kidneys, tubular and papil-
lar necrosis is observed and scattered necrotic hepatocytes are 
found in the liver. No overt CNS pathology is apparent, despite 
the frequent manifestation of neurological symptoms. Secondary 
bacterial infections such as pneumonia are common in AHF. 
The lesions consistently associated with fatal cases are present 
Figure 2. Model for Lassa virus pathogenesis. Macrophages and DCs represent early and preferred targets for Lassa virus (LASV) in 
human infection. However, instead of being recognized and presented as foreign antigen, LASV establishes productive infection that fails 
to activate the cells and perturbs their ability to stimulate T cells, contributing to immunosuppression. LASV infection in macrophages 
and in particular DCs does not result in excessive production of cytokines, but releases significant amounts of infectious virus. Infection 
of the liver results in enhanced levels of transaminases and hepatocellular necrosis. While the histopathology in the liver is too weak to 
account for liver failure, infection of hepatocytes may alter the production of serum proteins, possibly affecting hemostasis. Extensive 
viral replication in the adrenal cortex, where high viral loads are detected, may affect the production of mineralcorticoids leading to fluid 
imbalance. LASV can productively infect vascular endothelial cells without causing overt cytopathology and vascular lesions are mild in 
fatal Lassa fever. The mechanisms underlying the alterations in endothelial cell functions that precede shock and death in fatal Lassa 
fever are largely unknown and may involve direct effect of virus infection as well as effects mediated by as yet undefined soluble factors 
released by other cells. 
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in the lymphatic tissue with widespread necrosis of the splenic 
white pulp and in the cortical and paracortical areas of the lymph 
nodes. The bone marrow shows global cell depletion. The highest 
virus titers are found in the spleen, lymph nodes and lungs, and 
high levels of viral antigen are found in cells of the monocyte/
macrophage lineage in peripheral blood [71], lymphatic tissue, lung 
and liver [72]. Patients with AHF have very high levels of IFNs, 
TNF-a, and other inflammatory mediators that correlate with 
the severity of disease [73–75]. However, at present it is unclear if 
the enhanced levels of cytokines reflect mainly enhanced levels 
of viral replication and more widespread infection or if they play 
a role in immune-mediated pathology similar to fatal filovirus 
VHFs [62,63]. 
Virus-induced immunosuppression is also a hallmark of fatal 
infection with the South American HF viruses. Similar to LASV, 
JUNV efficiently targets DC early in infection, likely contribut-
ing to immunosuppression (Figure 2). In contrast to Lassa fever, 
AHF manifests with more pronounced hemorrhages, although the 
extent of vascular damage and blood loss does not account for the 
fatal outcome [16]. The hemorrhagic syndrome in AHF is attrib-
uted to coagulation alterations and marked thrombocytopenia, 
possibly in combination with virus and cytokine-induced vascular 
damage and does, in contrast to other VHF, generally not involve 
disseminated intravascular coagulation (TABle 1). 
Several lines of evidence implicate infection of vascular endothe-
lial cells in AHF pathogenesis. Infection of cultured endo thelial 
cells with JUNV did not cause overt cytopathic effects but altered 
expression of cell adhesion molecules ICAM-1 and VCAM-1 and 
reduced secretion of coagulation factors, such as the prothrombic 
von Willebrand factor (vWF) [76]. The lat-
ter finding seems to contradict clinical data 
showing increased vWF in sera of AHF 
patients [77] and the reason for this discrep-
ancy is likely another source of vWF in AHF 
in vivo, such as megakaryocytes/platelets. Of 
particular interest is the increased produc-
tion of the vaso active mediator NO and 
prostaglandin PGI
2
 in endothelial cells 
infected with a virulent strain of JUNV, but 
not an avirulent isolate [76], providing a first 
possible link between viral infection and the 
increased vascular permeability observed in 
fatal AHF cases. 
A hallmark of fatal AHFs are coagulation 
abnormalities, including thrombo cytopenia 
and low levels of platelet activity [78]. As 
in the case of Lassa fever, evidence for an 
inhibitor of platelet aggregation in plasma 
of infected patients has been found [60]. 
However, the exact nature of this inhibi-
tor remains elusive. Recent studies shed 
light on the mechanism of virus-induced 
thrombocytopenia employing an in vitro 
model of human CD43+ cells stimulated 
with thrombopoietin [79]. JUNV infection 
of CD43+ precursor cells did not affect proliferation and cell 
viability but markedly perturbed the differentiation of mega-
karyocytes resulting in reduced thrombopoiesis at the levels of 
proplatelet formation and platelet release. Interestingly, perturba-
tion of thrombopoiesis was not dependent on direct infection of 
cells, but seems to be, at least in part, mediated by a bystander 
effect that involves type I IFNs. A remarkable aspect of AHF is 
the fact that some patients die in absence of hemorrhagic disease 
and manifest mainly with neurological symptoms [16]. The patho-
physiological basis for the neurological syndrome that is present to 
a variable degree in AHF patients is currently largely unknown. 
MACV is also a rodent-borne pathogen that caused serious 
outbreaks of HF in Bolivia in the 1960s [80], but the number of 
cases has declined since. Human-to-human transmission has 
been reported [81]. GTOV emerged as the cause of Venezuelan 
HF in the 1990s [82,83]. Based on their close phylogenetic relation-
ship to JUNV, infections with MACV [84,85] and GTOV [82,83,86] 
resemble AHF in their pathology, clinical manifestations and 
mortality. 
While no specific treatments or vaccines have been established 
for MACV and GTOV, a live-attenuated JUNV has been devel-
oped and is used in high-risk groups in endemic areas [87]. Current 
therapy of AHF infection involves the administration of immune 
plasma from convalescent patients [88], which is effective when 
started during the first week of disease and critically depends 
on the titers of neutralizing antibodies. Immune plasma therapy 
reduces mortality from 15–30% to less than 1%. Circa 10% of 
patients develop a self-limiting late neurological syndrome, whose 
pathophysiology is unknown. 
Table 1. Comparison of Lassa fever with the South American 
arenavirus hemorrhagic fevers and Ebola hemorrhagic fever.
Parameter LASV JUNV MACV Ebola 
Fever Yes Yes Yes Yes
Hypotension Yes Yes Yes Yes
Hemorrhages Weak† Occasional Occasional Occasional
Lymphopenia Yes Yes Yes Yes
Hepatic lesions Yes Yes Yes Yes
Vascular lesions No No No No
Thrombocytopenia Rare Yes Yes Yes
Platelet dysfunction Mild Yes Yes Yes
DIC No‡ Rare§ Rare§ Yes
Infection of MP Yes Yes Yes Yes
Infection of DC Yes Yes Yes Yes
Elevated interferons No¶ Yes Yes Yes
Elevated cytokines No¶ Yes Yes Yes
†Hemorrhages in LASV are limited to mucosal surfaces and blood loss is mild. 
‡Fibrin deposits have been reported in rare cases.
§In isolated cases, there is biochemical evidence for DIC and detection of fibrin deposits.
¶No excessive levels of interferons and cytokines detected in Lassa fever patient sera.
DC: Dendritic cell; DIC: Disseminated intravascular coagulation; JUNV: Junin virus; LASV: Lassa virus; 
MACV: Machupo virus; MP: Macrophage.
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Insights into the pathogenesis of arenavirus 
hemorrhagic fevers from new animal models
The investigation of arenavirus pathogenesis critically depends on 
suitable animal models. Nonhuman primates are still considered 
the major relevant model for Lassa fever, in particular rhesus and 
cynomolgus monkeys (Macaca mulatta and Macaca fascicularis, 
respectively). Experimental studies in these nonhuman primates 
largely reproduce the pathology of human Lassa fever at the sys-
temic and histological level, including hepatocellular necrosis, inter-
stitial pneumonia, increased blood transaminase levels, and hemor-
rhagic signs and symptoms [50,51,89–94]. As in the human disease, 
the terminal shock syndrome includes hypovolemia, hypotension 
and acute respiratory distress. A recent study comparing antiviral 
immune responses between fatal and nonfatal LASV infection in 
cynomolgus monkeys revealed that fatal infection was associated 
with only weak activation of antiviral T cells and monocytes, a 
delayed and weak antibody response resulting in unchecked vire-
mia, shock and death. Nonfatal infection was characterized by a 
vigorous antiviral T-cell response, activation of monocytes and 
effective control of viral replication [50]. The similarities with clini-
cal findings in human Lassa fever underline the potential of this 
model for future studies. Marmosets have recently been described 
as an alternative nonhuman primate model for LASV infection 
[95]. Another powerful model for LASV infection in nonhuman 
primates uses the closely related LCMV, which is a BSL2/3 patho-
gen [96,97]. This model has recently been used for comprehensive 
transcriptome ana lysis in the blood and liver of rhesus monkeys 
infected with a lethal dose of LCMV that has provided an invalu-
able source for the search for candidate genes involved in arenavirus 
VHF pathogenesis and biomarkers for diagnostic purposes [98,99]. 
A major challenge in LASV research has been the lack of a 
mouse model for LASV that allows the application of useful 
mouse genetics for studies on LASV pathogenesis in vivo, mainly 
owing to the fact that normal laboratory mouse strains are resis-
tant to LASV infection. A recent study found that mice expressing 
humanized MHC class I failed to control LASV infection and 
developed fatal VHF [100]. Interestingly, in this model, depletion 
of T cells prevented disease, irrespective of viremia, indicating a 
role for T cells in VHF pathogenesis. It will be of great interest 
to compare the observations from this novel small animal model 
with established nonhuman primate models and human infec-
tion. Another important lesson learned from this novel model is 
to consider the possibility of T-cell-mediated pathology in the 
development of novel Lassa fever vaccine strategies.
Other important BSL2/3 models for arenavirus VHF are the 
infection of Pichinde virus in guinea pigs (reviewed in [101]) and 
the infection of Syrian golden hamsters with Pirital virus [102,103]. 
Several experimental animal models exist for JUNV pathogenesis, 
including mice [104–107], guinea pigs [108–110] and rats [111], as well 
as New and Old World primates [112–116]. A particularly interest-
ing small animal model for JUNV infection has recently been 
established using the JUNV Romero strain in guinea pigs and 
largely recapitulates the pathological findings in human AHF [117], 
holding great potential for basic research on JUNV pathogenesis 
and evaluation of novel drugs and vaccine candidates. 
Expert commentary & five-year view
The past years have seen an impressive progress in our under-
standing of the basic molecular and cellular biology of arena-
viruses. In particular, the advent of a powerful reverse genetic 
system for arenaviruses [118–120] paves the way for sophisticated 
structure–function studies and the molecular dissection of the 
mechanisms of virus–host interaction in vitro and also in vivo. 
Over the years, much has been learned about the pathogenesis 
of arenaviruses at the cellular level, in particular their ability 
to subvert the host cell’s innate antiviral defenses [45–49]. Key 
IFN antagonists of arenaviruses have been discovered and the 
mechanisms by which the viruses block innate antiviral signaling 
elucidated. Other in vitro studies have shed light on the impact 
of arenavirus infection on the differentiation and function of 
cells targeted by hemorrhagic arenaviruses in vivo, including 
APCs such as macrophages and DCs [53,54], endothelial cells [76], 
and megakaryocytes [79] involved in platelet formation. At the 
same time, novel animal models provided important new infor-
mation about the interaction of hemorrhagic arenaviruses with 
the host’s adaptive immune system, in particular virus-induced 
immunosuppression, and provided the first hints towards an 
understanding of the terminal hemorrhagic shock syndrome 
[50,98–100,117]. However, many questions remain unanswered. In 
particular, the pathogenesis of Lassa fever appears to be rather 
atypical with little evidence for immunopathological mecha-
nisms and largely unknown mechanisms underlying the vascular 
dysfunction involved in the terminal shock syndrome. As more 
subtle, direct effects of virus replication and gene expression may 
be responsible for the perturbation of endothelial cell function, 
future research involving suitable cell culture models for human 
endothelium, which allow detailed ana lysis of virus-induced cell 
biological and biochemical alterations, will be of great impor-
tance. Advances in endothelial cell culture, combined with high 
resolution confocal microscopy and the ability to measure endo-
thelial cell functions such as transendothelial electrical resistance 
and hydraulic conductivity in live cells will allow monitoring 
of subtle, virus-induced functional changes as a consequence 
of arenavirus infection. The availability of a powerful reverse 
genetic system for arenaviruses [118–120] combined with suitable 
well-controlled in vitro experimental systems may allow the iden-
tification of viral proteins and their cellular targets implicated in 
virus-induced changes in the major cell types targeted by LASV 
in vivo, including APCs such as DCs and vascular endothelial 
cells. The identification of cellular proteins and signaling path-
ways affected by virus infection and the characterization of the 
molecular interactions involved over the next 5 years will open 
new avenues for the development of drugs that could prevent 
arenavirus-induced endothelial cell dysfunction associated with 
fatal arenavirus VHFs. In addition, recently developed novel 
diagnostic tools, including more sensitive molecular probes for 
viral nucleic acids and new antibodies against LASV proteins, 
will allow a better assessment of the extent of viral infection of 
the endothelium and consequent functional alterations in vivo. 
The recent development of novel and promising small animal 
models for human Lassa fever and AHF, as well as refinements 
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of established nonhuman primate models for LASV will greatly 
facilitate the validation of mechanistic findings obtained in vitro 
in the systemic context and allow evaluation of novel therapeutic 
strategies in preclinical studies. 
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Key issues
• Viral hemorrhagic fevers (VHFs) caused by arenaviruses are among the most devastating emerging human diseases and represent 
serious public health problems. There is no licensed vaccine against these pathogens and therapeutic options are limited.
• A particular concern with arenaviruses is the continued emergence of new viruses that are associated with severe VHFs, as illustrated by 
the emergence of Chapare virus in 2003 and Lujo virus in 2008.
• Arenavirus VHFs in humans are acute diseases characterized by fever and, in severe cases, different degrees of hemorrhages associated 
with a shock syndrome in the terminal stage. Blood loss in arenavirus VHF does not account for the fatal outcome, and the 
pathophysiology underlying the terminal shock syndrome is not yet fully understood.
• Based on its clinical and pathological features, Lassa fever presents as a rather atypical VHF. Postmortem examination of fatal Lassa 
fever cases show surprisingly little tissue damage and only modest inflammation with absence of disseminated intravascular coagulation 
in the terminal stage. 
• Fatal arenavirus VHFs are characterized by marked immunosuppression of the host, resulting in uncontrolled viral spread and replication 
associated with hemorrhagic shock. The immunosuppression associated with fatal disease is likely related to the fact that hemorrhagic 
arenaviruses efficiently target antigen-presenting cells such as macrophages and, in particular, dendritic cells, and perturb their function 
in antigen presentation.
• Arenaviruses can efficiently block the host cell’s antiviral interferon response with the viral nucleoprotein and, in some species, also the 
Z protein, acting as interferon antagonists. Efficient blocking of the host innate antiviral defense by arenaviruses may contribute to the 
inability of the host to contain virus infection in fatal arenavirus VHF.
• A number of novel animal models for VHFs have been developed in past years and hold much promise for future studies on arenavirus 
pathology in vivo.
References
Papers of special note have been highlighted as:
•  of interest
••  of considerable interest
1 Geisbert TW, Jahrling PB. Exotic 
emerging viral diseases: progress and 
challenges. Nat. Med. 10(12 Suppl.), 
S110–S121 (2004).
2 Buchmeier MJ, de la Torre JC, Peters CJ. 
Arenaviridae: the viruses and their 
replication. In: Fields Virology. Knipe DL, 
Howley PM (Eds.) Lippincott-Raven, 
Philadelphia, PA, USA, 1791–1828 (2007).
3 McCormick JB, Fisher-Hoch SP. Lassa 
fever. Curr. Top. Microbiol. Immunol. 262, 
75–109 (2002).
4 Barton LL, Mets MB, Beauchamp CL. 
Lymphocytic choriomeningitis virus: 
emerging fetal teratogen. Am. J. Obstet. 
Gynecol. 187(6), 1715–1716 (2002).
5 Jamieson DJ, Kourtis AP, Bell M, 
Rasmussen SA. Lymphocytic 
choriomeningitis virus: an emerging 
obstetric pathogen? Am. J. Obstet. Gynecol. 
194(6), 1532–1536 (2006).
6 Fischer SA, Graham MB, Kuehnert MJ et al. 
Transmission of lymphocytic choriomeningitis 
virus by organ transplantation. N. Engl. J. 
Med. 354(21), 2235–2249 (2006).
7 Palacios G, Druce J, Du L et al. A new 
arenavirus in a cluster of fatal transplant-
associated diseases. N. Engl. J. Med. 
358(10), 991–998 (2008).
•	 Describes	the	discovery	of	a	new	
arenavirus	associated	with	fatal	cases	of	
infection	in	transplantation	patients	and	
is	of	particular	interest	regarding	the	
technologies	used	for	pathogen	discovery.
8 Borio L, Inglesby T, Peters CJ et al. 
Hemorrhagic fever viruses as biological 
weapons: medical and public health 
management. JAMA 287(18), 2391–2405 
(2002).
9 Emonet SF, de la Torre JC, Domingo E, 
Sevilla N. Arenavirus genetic diversity and 
its biological implications. Infect. Genet. 
Evol. 9(4), 417–429 (2009).
10 Charrel RN, de Lamballerie X, Emonet S. 
Phylogeny of the genus Arenavirus. Curr. 
Opin. Microbiol. 11(4), 362–368 (2008).
11 (CDC) CfDCaP. Fatal illnesses associated 
with a new world arenavirus – California, 
1999–2000. MMWR Morb. Mortal. Wkly 
Rep. 49(31), 709–711 (2000).
12 Enserink M. Emerging diseases. New 
arenavirus blamed for recent deaths in 
California. Science 289(5481), 842–843 
(2000).
13 Charrel RN, Lemasson JJ, Garbutt M et al. 
New insights into the evolutionary 
relationships between arenaviruses 
provided by comparative analysis of small 
and large segment sequences. Virology 
317(2), 191–196 (2003).
14 Delgado S, Erickson BR, Agudo R et al. 
Chapare virus, a newly discovered 
arenavirus isolated from a fatal 
hemorrhagic fever case in Bolivia. PLoS 
Pathog. 4(4), e1000047 (2008).
•	 Reports	the	discovery	of	Chapare	virus,	a	
new	arenavirus	associated	with	fatal	viral	
hemorrhagic	fevers	(VHFs)	in	Bolivia.
15 Briese T, Paweska JT, McMullan LK et al. 
Genetic detection and characterization of 
Lujo virus, a new hemorrhagic fever-
www.expert-reviews.com 57
ReviewPathogenesis of arenavirus hemorrhagic fevers
associated arenavirus from southern Africa. 
PLoS Pathog. 5(5), e1000455 (2009).
••	 Describes	the	identification	of	a	new	
arenavirus	in	South	Africa	that	has	been	
associated	with	fatal	VHF	and	suspected	
human-to-human	transmission.	
16 Weissenbacher MC, Laguens RP, Coto CE. 
Argentine hemorrhagic fever. Curr. Top. 
Microbiol. Immunol. 134, 79–116 (1987).
17 de la Torre JC. Molecular and cell biology of 
the prototypic arenavirus LCMV: implications 
for understanding and combating 
hemorrhagic fever arenaviruses. Ann. NY 
Acad. Sci. 1171(Suppl. 1), E57–E64 (2009).
18 Lenz O, ter Meulen J, Klenk HD, Seidah 
NG, Garten W. The Lassa virus 
glycoprotein precursor GP-C is 
proteolytically processed by subtilase 
SKI-1/S1P. Proc. Natl Acad. Sci. USA 
98(22), 12701–12705 (2001).
19 Beyer WR, Popplau D, Garten W, von Laer 
D, Lenz O. Endoproteolytic processing of 
the lymphocytic choriomeningitis virus 
glycoprotein by the subtilase SKI-1/S1P. 
J. Virol. 77(5), 2866–2872 (2003).
20 Rojek JM, Lee AM, Nguyen N, Spiropoulou 
CF, Kunz S. Site 1 protease is required for 
proteolytic processing of the glycoproteins of 
the South American hemorrhagic fever 
viruses Junin, Machupo, and Guanarito. 
J. Virol. 82(12), 6045–6051 (2008).
21 Cao W, Henry MD, Borrow P et al. 
Identification of a-dystroglycan as a 
receptor for lymphocytic choriomeningitis 
virus and Lassa fever virus [see comments]. 
Science 282(5396), 2079–2081 (1998).
22 Kunz S. Receptor binding and cell entry of 
Old World arenaviruses reveal novel aspects 
of virus–host interaction. Virology 387(2), 
245–249 (2009).
23 Radoshitzky SR, Abraham J, Spiropoulou 
CF et al. Transferrin receptor 1 is a cellular 
receptor for New World haemorrhagic fever 
arenaviruses. Nature 446(7131), 92–96 
(2007).
••	 Describes	the	discovery	of	human	TfR1	as	
the	receptor	for	the	South	American	
hemorrhagic	fever	arenaviruses.	The	
discovery	of	the	cellular	receptor	of	these	
viruses	is	of	great	importance	considering	
their	pathogenesis.
24 Borrow P, Oldstone MB. Mechanism of 
lymphocytic choriomeningitis virus entry 
into cells. Virology 198(1), 1–9 (1994).
25 Martinez MG, Cordo SM, Candurra NA. 
Characterization of Junin arenavirus cell 
entry. J. Gen. Virol. 88(Pt 6), 1776–1784 
(2007).
26 Quirin K, Eschli B, Scheu I, Poort L, 
Kartenbeck J, Helenius A. Lymphocytic 
choriomeningitis virus uses a novel endocytic 
pathway for infectious entry via late 
endosomes. Virology 378(1), 21–33 (2008).
27 Rojek JM, Perez M, Kunz S. Cellular entry 
of lymphocytic choriomeningitis virus. 
J. Virol. 82(3), 1505–1517 (2008).
28 Rojek JM, Sanchez AB, Nguyen NT, de la 
Torre JC, Kunz S. Different mechanisms of 
cell entry by human-pathogenic Old World 
and New World arenaviruses. J. Virol. 
82(15), 7677–7687 (2008).
29 Perez M, Craven RC, de la Torre JC. The 
small RING finger protein Z drives 
arenavirus budding: implications for 
antiviral strategies. Proc. Natl Acad. Sci. 
USA 100(22), 12978–12983 (2003). 
30 Strecker T, Eichler R, Meulen J et al. 
Lassa virus Z protein is a matrix protein 
and sufficient for the release of virus-like 
particles [corrected]. J. Virol. 77(19), 
10700–10705 (2003).
31 Frame JD, Baldwin JM Jr, Gocke DJ, 
Troup JM. Lassa fever, a new virus disease 
of man from West Africa. I. Clinical 
description and pathological findings. Am. 
J. Trop. Med. Hyg. 19(4), 670–676 (1970).
32 Buckley SM, Casals J. Lassa fever, a new 
virus disease of man from West Africa. 3. 
Isolation and characterization of the virus. 
Am. J. Trop. Med. Hyg. 19(4), 680–691 
(1970).
33 Monath TP, Newhouse VF, Kemp GE, 
Setzer HW, Cacciapuoti A. Lassa virus 
isolation from Mastomys natalensis rodents 
during an epidemic in Sierra Leone. Science 
185(147), 263–265 (1974).
34 Safronetz D, Lopez JE, Sogoba N et al. 
Detection of Lassa virus, Mali. Emerg. 
Infect. Dis. 16(7), 1123–1126 (2010).
35 Richmond JK, Baglole DJ. Lassa fever: 
epidemiology, clinical features, and social 
consequences. Br. Med. J. 327(7426), 
1271–1275 (2003).
36 McCormick JB, Webb PA, Krebs JW, 
Johnson KM, Smith ES. A prospective 
study of the epidemiology and ecology of 
Lassa fever. J. Infect. Dis. 155(3), 437–444 
(1987).
37 Fisher-Hoch SP, Tomori O, Nasidi A et al. 
Review of cases of nosocomial Lassa fever 
in Nigeria: the high price of poor medical 
practice. Br. Med. J. 311(7009), 857–859 
(1995).
38 McCormick JB, King IJ, Webb PA et al. A 
case–control study of the clinical diagnosis 
and course of Lassa fever. J. Infect. Dis. 
155(3), 445–455 (1987).
39 Price ME, Fisher-Hoch SP, Craven RB, 
McCormick JB. A prospective study of 
maternal and fetal outcome in acute Lassa 
fever infection during pregnancy. Br. Med. 
J. 297(6648), 584–587 (1988).
40 Cummins D, McCormick JB, Bennett D 
et al. Acute sensorineural deafness in Lassa 
fever. JAMA 264(16), 2093–2096 (1990).
41 Johnson KM, McCormick JB, Webb PA, 
Smith ES, Elliott LH, King IJ. Clinical 
virology of Lassa fever in hospitalized patients. 
J. Infect. Dis. 155(3), 456–464 (1987).
42 Walker DH, McCormick JB, Johnson KM 
et al. Pathologic and virologic study of fatal 
Lassa fever in man. Am. J. Pathol. 107(3), 
349–356 (1982).
43 McCormick JB, Walker DH, King IJ et al. 
Lassa virus hepatitis: a study of fatal Lassa 
fever in humans. Am. J. Trop. Med. Hyg. 
35(2), 401–407 (1986).
44 Habjan M, Andersson I, Klingstrom J et al. 
Processing of genome 5’ termini as a 
strategy of negative-strand RNA viruses to 
avoid RIG-I-dependent interferon 
induction. PLoS One 3(4), e2032 (2008).
45 Zhou S, Cerny AM, Zacharia A, Fitzgerald 
KA, Kurt-Jones EA, Finberg RW. 
Induction and inhibition of the type I 
interferon responses by distinct 
components of lymphocytic 
choriomeningitis virus. J. Virol. 84(18), 
9452–9462 (2010).
46 Martinez-Sobrido L, Zuniga EI, Rosario 
D, Garcia-Sastre A, de la Torre JC. 
Inhibition of the type I interferon response 
by the nucleoprotein of the prototypic 
arenavirus lymphocytic choriomeningitis 
virus. J. Virol. 80(18), 9192–9199 (2006).
••	 Identified	the	nucleoprotein	of	arenaviruses	
as	a	potent	antagonist	of	the	cellular	type	I	
interferon	response.	This	was	the	first	
report	demonstrating	the	existence	of	an	
interferon	antagonist	in	arenaviruses.	
47 Martinez-Sobrido L, Emonet S, Giannakas 
P, Cubitt B, Garcia-Sastre A, de la Torre 
JC. Identification of amino acid residues 
critical for the anti-interferon activity of the 
nucleoprotein of the prototypic arenavirus 
lymphocytic choriomeningitis virus. 
J. Virol. 83(21), 11330–11340 (2009).
48 Martinez-Sobrido L, Giannakas P, Cubitt 
B, Garcia-Sastre A, de la Torre JC. 
Differential inhibition of type I interferon 
induction by arenavirus nucleoproteins. 
J. Virol. 81(22), 12696–12703 (2007).
49 Fan L, Briese T, Lipkin WI. Z proteins of 
New World arenaviruses bind RIG-I and 
interfere with type I interferon induction. 
J. Virol. 84(4), 1785–1791 (2010).
Expert Rev. Anti Infect. Ther. 9(1), (2011)58
Review Moraz & Kunz
50 Baize S, Marianneau P, Loth P et al. Early 
and strong immune responses are 
associated with control of viral replication 
and recovery in lassa virus-infected 
cynomolgus monkeys. J. Virol. 83(11), 
5890–5903 (2009).
51 Fisher-Hoch SP, Hutwagner L, Brown B, 
McCormick JB. Effective vaccine for lassa 
fever. J. Virol. 74(15), 6777–6783 (2000).
52 ter Meulen J, Badusche M, Kuhnt K et al. 
Characterization of human CD4(+) T-cell 
clones recognizing conserved and variable 
epitopes of the Lassa virus nucleoprotein. 
J. Virol. 74(5), 2186–2192 (2000).
53 Baize S, Kaplon J, Faure C, Pannetier D, 
Georges-Courbot MC, Deubel V. Lassa 
virus infection of human dendritic cells 
and macrophages is productive but fails to 
activate cells. J. Immunol. 172(5), 
2861–2869 (2004).
54 Mahanty S, Hutchinson K, Agarwal S, 
McRae M, Rollin PE, Pulendran B. 
Cutting edge: impairment of dendritic cells 
and adaptive immunity by Ebola and Lassa 
viruses. J. Immunol. 170(6), 2797–2801 
(2003).
•	 Described	the	perturbation	of	antigen	
presentation	to	T	cells	by	dendritic	cells	
upon	Lassa	virus	(LASV)	infection.	
55 Mahanty S, Bausch DG, Thomas RL et al. 
Low levels of interleukin-8 and interferon-
inducible protein-10 in serum are associated 
with fatal infections in acute Lassa fever. J. 
Infect. Dis. 183(12), 1713–1721 (2001).
56 Reignier T, Oldenburg J, Noble B et al. 
Receptor use by pathogenic arenaviruses. 
Virology 353(1), 111–120 (2006).
57 Rojek JM, Spiropoulou CF, Campbell KP, 
Kunz S. Old World and Clade C New 
World arenaviruses mimic the molecular 
mechanism of receptor recognition used by 
a-dystroglycan’s host-derived ligands. J. 
Virol. 81(11), 5685–5695 (2007).
58 McNally JM, Zarozinski CC, Lin MY, 
Brehm MA, Chen HD, Welsh RM. Attrition 
of bystander CD8 T cells during virus-
induced T-cell and interferon responses. 
J. Virol. 75(13), 5965–5976 (2001).
59 Fisher-Hoch S, McCormick JB, Sasso D, 
Craven RB. Hematologic dysfunction in 
Lassa fever. J. Med. Virol. 26(2), 127–135 
(1988).
60 Cummins D, Fisher-Hoch SP, Walshe KJ 
et al. A plasma inhibitor of platelet 
aggregation in patients with Lassa fever.  
Br. J. Haematol. 72(4), 543–548 (1989).
61 Fisher-Hoch SP, Mitchell SW, Sasso DR, 
Lange JV, Ramsey R, McCormick JB. 
Physiological and immunologic 
disturbances associated with shock in a 
primate model of Lassa fever. J. Infect. Dis. 
155(3), 465–474 (1987).
62 Aleksandrowicz P, Wolf K, Falzarano D, 
Feldmann H, Seebach J, Schnittler H. Viral 
haemorrhagic fever and vascular alterations. 
Hamostaseologie 28(1–2), 77–84 (2008).
63 Schnittler HJ, Feldmann H. Viral 
hemorrhagic fever – a vascular disease? 
Thromb. Haemost. 89(6), 967–972 (2003).
64 Lukashevich IS, Maryankova R, Vladyko 
AS et al. Lassa and Mopeia virus replication 
in human monocytes/macrophages and in 
endothelial cells: different effects on IL-8 
and TNF-a gene expression. J. Med. Virol. 
59(4), 552–560 (1999).
65 Arribalzaga RA. New epidemic disease due to 
unidentified germ: nephrotoxic, leukopenic 
and enanthematous hyperthermia. Dia. Med. 
27(40), 1204–1210 (1955).
66 Parodi AS, Greenway DJ, Rugiero HR et al. 
Concerning the epidemic outbreak in Junin. 
Dia. Med. 30(62), 2300–2301 (1958).
67 Peters CJ. Human infection with 
arenaviruses in the Americas. Curr. Top. 
Microbiol. Immunol. 262, 65–74 (2002).
68 Harrison LH, Halsey NA, McKee KT Jr 
et al. Clinical case definitions for argentine 
hemorrhagic fever. Clin. Infect. Dis. 28(5), 
1091–1094 (1999).
69 Kenyon RH, McKee KT Jr, Zack PM et al. 
Aerosol infection of rhesus macaques with 
Junin virus. Intervirology 33(1), 23–31 
(1992).
70 de Bracco MM, Rimoldi MT, Cossio PM 
et al. Argentine hemorrhagic fever. 
Alterations of the complement system and 
anti-Junin-virus humoral response. N. 
Engl. J. Med. 299(5), 216–221 (1978).
71 Ambrosio AM, Enria DA, Maiztegui JI. 
Junin virus isolation from lympho-
mononuclear cells of patients with 
Argentine hemorrhagic fever. Intervirology 
25(2), 97–102 (1986).
72 Gonzalez PH, Cossio PM, Arana R, 
Maiztegui JI, Laguens RP. Lymphatic 
tissue in Argentine hemorrhagic fever. 
Pathologic features. Arch. Pathol. Lab. Med. 
104(5), 250–254 (1980).
73 Levis SC, Saavedra MC, Ceccoli C et al. 
Correlation between endogenous interferon 
and the clinical evolution of patients with 
Argentine hemorrhagic fever. J. Interferon 
Res. 5(3), 383–389 (1985).
74 Heller MV, Saavedra MC, Falcoff R, 
Maiztegui JI, Molinas FC. Increased tumor 
necrosis factor-a levels in Argentine 
hemorrhagic fever. J. Infect. Dis. 166(5), 
1203–1204 (1992).
75 Marta RF, Montero VS, Hack CE, Sturk A, 
Maiztegui JI, Molinas FC. Proinflammatory 
cytokines and elastase-a-1-antitrypsin in 
Argentine hemorrhagic fever. Am. J. Trop. 
Med. Hyg. 60(1), 85–89 (1999).
76 Gomez RM, Pozner RG, Lazzari MA et al. 
Endothelial cell function alteration after 
Junin virus infection. Thromb. Haemost. 
90(2), 326–333 (2003).
77 Molinas FC, de Bracco MM, Maiztegui 
JI. Hemostasis and the complement 
system in Argentine hemorrhagic fever. 
Rev. Infect. Dis. 11(Suppl. 4), S762–S770 
(1989).
78 Heller MV, Marta RF, Sturk A et al. Early 
markers of blood coagulation and 
fibrinolysis activation in Argentine 
hemorrhagic fever. Thromb. Haemost. 
73(3), 368–373 (1995).
79 Pozner RG, Ure AE, Jaquenod de Giusti C 
et al. Junin virus infection of human 
hematopoietic progenitors impairs in vitro 
proplatelet formation and platelet release 
via a bystander effect involving type I IFN 
signaling. PLoS Pathog. 6(4), e1000847 
(2010).
••	 Interesting	paper	describing	a	possible	
mechanism	by	which	Junin	virus	infection	
perturbs	platelet	formation.
80 Johnson KM, Kuns ML, Mackenzie RB, 
Webb PA, Yunker CE. Isolation of 
Machupo virus from wild rodent Calomys 
callosus. Am. J. Trop. Med. Hyg. 15(1), 
103–106 (1966).
81 Kilgore PE, Peters CJ, Mills JN et al. 
Prospects for the control of Bolivian 
hemorrhagic fever. Emerg. Infect. Dis. 1(3), 
97–100 (1995).
82 Salas R, de Manzione N, Tesh RB et al. 
Venezuelan haemorrhagic fever. Lancet 
338(8774), 1033–1036 (1991).
83 Tesh RB, Jahrling PB, Salas R, Shope RE. 
Description of Guanarito virus 
(Arenaviridae: Arenavirus), the etiologic 
agent of Venezuelan hemorrhagic fever. Am. 
J. Trop. Med. Hyg. 50(4), 452–459 (1994).
84 Stinebaugh BJ, Schloeder FX, Johnson 
KM, Mackenzie RB, Entwisle G, De Alba 
E. Bolivian hemorrhagic fever. A report of 
four cases. Am. J. Med. 40(2), 217–230 
(1966).
85 Johnson KM, Halstead SB, Cohen SN. 
Hemorrhagic fevers of Southeast Asia and 
South America: a comparative appraisal. 
Prog. Med. Virol. 9, 105–158 (1967).
86 de Manzione N, Salas RA, Paredes H et al. 
Venezuelan hemorrhagic fever: clinical and 
epidemiological studies of 165 cases. Clin. 
Infect. Dis. 26(2), 308–313 (1998).
www.expert-reviews.com 59
ReviewPathogenesis of arenavirus hemorrhagic fevers
87 Enria DA, Barrera Oro JG. Junin virus 
vaccines. Curr. Top. Microbiol. Immunol. 
263, 239–261 (2002).
88 Enria DA, Briggiler AM, Sanchez Z. 
Treatment of Argentine hemorrhagic fever. 
Antiviral Res. 78(1), 132–139 (2008).
89 Callis RT, Jahrling PB, DePaoli A. 
Pathology of Lassa virus infection in the 
rhesus monkey. Am. J. Trop. Med. Hyg. 
31(5), 1038–1045 (1982).
90 Geisbert TW, Jones S, Fritz EA et al. 
Development of a new vaccine for the 
prevention of Lassa fever. PLoS Med. 2(6), 
e183 (2005).
91 Jahrling PB, Hesse RA, Eddy GA, Johnson 
KM, Callis RT, Stephen EL. Lassa virus 
infection of rhesus monkeys: pathogenesis 
and treatment with ribavirin. J. Infect. Dis. 
141(5), 580–589 (1980).
92 Jahrling PB, Peters CJ. Passive antibody 
therapy of Lassa fever in cynomolgus 
monkeys: importance of neutralizing 
antibody and Lassa virus strain. Infect. 
Immun. 44(2), 528–533 (1984).
93 Jahrling PB, Peters CJ, Stephen EL. 
Enhanced treatment of Lassa fever by 
immune plasma combined with ribavirin in 
cynomolgus monkeys. J. Infect. Dis. 149(3), 
420–427 (1984).
94 Walker DH, Johnson KM, Lange JV, 
Gardner JJ, Kiley MP, McCormick JB. 
Experimental infection of rhesus monkeys 
with Lassa virus and a closely related 
arenavirus, Mozambique virus. J. Infect. 
Dis. 146(3), 360–368 (1982).
95 Carrion R Jr, Brasky K, Mansfield K et al. 
Lassa virus infection in experimentally 
infected marmosets: liver pathology and 
immunophenotypic alterations in target 
tissues. J. Virol. 81(12), 6482–6490 
(2007).
96 Lukashevich IS, Djavani M, Rodas JD 
et al. Hemorrhagic fever occurs after 
intravenous, but not after intragastric, 
inoculation of rhesus macaques with 
lymphocytic choriomeningitis virus. J. 
Med. Virol. 67(2), 171–186 (2002).
97 Lukashevich IS, Tikhonov I, Rodas JD 
et al. Arenavirus-mediated liver 
pathology: acute lymphocytic 
choriomeningitis virus infection of rhesus 
macaques is characterized by high-level 
interleukin-6 expression and hepatocyte 
proliferation. J. Virol. 77(3), 1727–1737 
(2003).
98 Djavani MM, Crasta OR, Zapata JC et al. 
Early blood profiles of virus infection in a 
monkey model for Lassa fever. J. Virol. 
81(15), 7960–7973 (2007).
•	 Interesting	paper	characterizing	the	
protective	immune	response	against	
LASV	in	a	relevant	human	primate	model.	
99 Djavani M, Crasta OR, Zhang Y et al. Gene 
expression in primate liver during viral 
hemorrhagic fever. Virol. J. 6, 20 (2009).
100 Flatz L, Rieger T, Merkler D et al. T 
cell-dependence of Lassa fever pathogenesis. 
PLoS Pathog. 6(3), e1000836 (2010).
•	 Describes	a	new	small	animal	model	for	
LASV	infection	using	mice	transgenic	for	
human	MHC.
101 Liang Y, Lan S, Ly H. Molecular 
determinants of Pichinde virus infection of 
guinea pigs – a small animal model system 
for arenaviral hemorrhagic fevers. Ann. NY 
Acad. Sci. 1171(Suppl. 1), E65–E74 (2009).
102 Xiao SY, Zhang H, Yang Y, Tesh RB. 
Pirital virus (Arenaviridae) infection in the 
syrian golden hamster, Mesocricetus auratus: 
a new animal model for arenaviral 
hemorrhagic fever. Am. J. Trop. Med. Hyg. 
64(3–4), 111–118 (2001).
103 Sbrana E, Mateo RI, Xiao SY, Popov VL, 
Newman PC, Tesh RB. Clinical laboratory, 
virologic, and pathologic changes in 
hamsters experimentally infected with 
Pirital virus (Arenaviridae): a rodent model 
of Lassa fever. Am. J. Trop. Med. Hyg. 
74(6), 1096–1102 (2006).
104 Weissenbacher MC, de Guerrero LB, 
Boxaca MC. Experimental biology and 
pathogenesis of Junin virus infection in 
animals and man. Bull. World Health 
Organ. 52(4–6), 507–515 (1975).
105 Barrios HA, Rondinone SN, Blejer JL, 
Giovanniello OA, Nota NR. Development 
of specific immune response in mice 
infected with Junin virus. Acta. Virol. 
26(3), 156–164 (1982).
106 Weissenbacher MC, Calello MA, Quintans 
CJ, Panisse H, Woyskowsky NM, Zannoli 
VH. Junin virus infection in genetically 
athymic mice. Intervirology 19(1), 1–5 
(1983).
107 Campetella OE, Galassi NV, Sanjuan N, 
Barrios HA. Susceptible adult murine 
model for Junin virus. J. Med. Virol. 26(4), 
443–451 (1988).
108 Scolaro LA, Mersich SE, Damonte EB. 
Experimental infection of suckling mice 
with a host range mutant of Junin virus. J. 
Med. Virol. 34(4), 237–240 (1991).
109 Kenyon RH, Green DE, Maiztegui JI, 
Peters CJ. Viral strain dependent 
differences in experimental Argentine 
hemorrhagic fever (Junin virus) infection 
of guinea pigs. Intervirology 29(3), 133–143 
(1988).
110 Kenyon RH, Green DE, Eddy GA, Peters 
CJ. Treatment of junin virus-infected 
guinea pigs with immune serum: 
development of late neurological disease. J. 
Med. Virol. 20(3), 207–218 (1986).
111 Remesar MC, Blejer JL, Lerman GD, 
Dejean C, Nejamkis MR. Protection 
against encephalitis in rats caused by a 
pathogenic strain of the Junin virus, using 
peripheral inoculation of an attenuated 
strain. Rev. Argent. Microbiol. 21(3–4), 
120–126 (1989).
112 Weissenbacher MC, Calello MA, Colillas 
OJ, Rondinone SN, Frigerio MJ. Argentine 
hemorrhagic fever: a primate model. 
Intervirology 11(6), 363–365 (1979).
113 McKee KT Jr, Mahlandt BG, Maiztegui JI, 
Eddy GA, Peters CJ. Experimental 
Argentine hemorrhagic fever in rhesus 
macaques: viral strain-dependent clinical 
response. J. Infect. Dis. 152(1), 218–221 
(1985).
114 McKee KT Jr, Green DE, Mahlandt BG 
et al. Infection of Cebus monkeys with 
Junin virus. Medicina (B Aires) 45(2), 
144–152 (1985).
115 Avila MM, Samoilovich SR, Laguens RP, 
Merani MS, Weissenbacher MC. Protection 
of Junin virus-infected marmosets by 
passive administration of immune serum: 
association with late neurologic signs. J. 
Med. Virol. 21(1), 67–74 (1987).
116 Carballal G, Oubina JR, Molinas FC et al. 
Intracerebral infection of Cebus apella with 
the XJ-Clone 3 strain of Junin virus. J. 
Med. Virol. 21(3), 257–268 (1987).
117 Yun NE, Linde NS, Dziuba N et al. 
Pathogenesis of XJ and Romero strains of 
Junin virus in two strains of guinea pigs. Am. 
J. Trop. Med. Hyg. 79(2), 275–282 (2008).
•	 Interesting	animal	model	for	arenavirus	
viral	hemorrhagic	fever	using	the	Romero	
strain	of	Junin	virus	in	guinea	pigs	that	
recapitulates	many	aspect	of	viral	
pathogenesis	seen	in	the	human	disease.	
118 Sanchez AB, de la Torre JC. Rescue of the 
prototypic arenavirus LCMV entirely from 
plasmid. Virology 350(2), 370–380 (2006).
119 Flatz L, Bergthaler A, de la Torre JC, 
Pinschewer DD. Recovery of an arenavirus 
entirely from RNA polymerase I/II-driven 
cDNA. Proc. Natl Acad. Sci. USA 103(12), 
4663–4668 (2006).
120 Albarino CG, Bergeron E, Erickson BR, 
Khristova ML, Rollin PE, Nichol ST. 
Efficient reverse genetics generation of 
infectious Junin viruses differing in 
glycoprotein processing. J. Virol. 83(11), 
5606–5614 (2009).
